IMTX Immatics N.V.

NASDAQ
$8.93

Immatics N.V. (IMTX) is expected to report earnings on November 17, 2026, before the market open. The consensus earnings estimate is a loss of $0.57 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -1.4% since its last earnings release on August 18, 2026.

Immatics N.V. Missed Consensus Estimates
Tuesday, August 18, 2026 · 7:00 AM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 17
Tuesday · 7:00 AM ET
Earnings Whisper
-
vs ($0.57)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $8.99

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Immatics N.V.

Immatics N.V. engages in the discovery of targets for cancer immunotherapies. It is developing targeted immunotherapies with focus on treating solid tumors. Immatics N.V., formerly known as ARYA SCIENCES, is based in Tuebingen, Germany.

Sector

Healthcare

Industry

Biotechnology

Held By 1 ETFs, by dollar flow